Results 171 to 180 of about 1,991,569 (312)

Clinical Trials Registration

PLoS Medicine, 2006
Rockhold, Frank W, Krall, Ronald L
openaire   +3 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial.

JAMA Dermatol
Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF.   +6 more
europepmc   +1 more source

Clinical trial landscape of cellular therapies in bladder cancer. [PDF]

Int J Surg
Zhang Y, Lv S, Li Z, Wang X, Zhu Y.
europepmc   +1 more source

Comparison of King Vision video laryngoscope and Macintosh laryngoscope: a prospective randomized controlled clinical trial

, 2018
Başar Erdivanlı, Ahmet Şen, Şule Batçık, Tolga Koyuncu, Hızır Kazdal   +4 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Yoga for Opioid Withdrawal and Autonomic Regulation: A Randomized Clinical Trial.

JAMA Psychiatry
Goutham S, Bhargav H, Holla B, Mahadevan J, Nagendra RP, Jasti N, Narasimha VL, Mehta UM, Varambally S, Venkatasubramanian G, Chand P, Gangadhar BN, Hill KP, Keshavan M, Murthy P.   +14 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

When LOFTy Ideals Meet Clinical Trial Reality. [PDF]

Ann Am Thorac Soc
Pamidi S, Zarychanski R, Owens RL.
europepmc   +1 more source

Ethics guidelines for clinical trials to be revised [PDF]

, 2008
Peter V. O'Neil
openalex   +1 more source